TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 2.77 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Ophthalmic Drugs market has also been witnessing the trend of emergence of personalized medicines. However, the increasing use of complementary and alternative medicine could pose a challenge to the growth of this market.
TechNavio's report, the Global Non-small Cell Lung Cancer Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are AstraZeneca plc., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and Sanofi S.A.
The other vendors mentioned in the report are Bristol-Myers Squibb Co., GlaxoSmithKline Plc., Novartis AG, and OSI Pharmaceuticals Inc.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. Introduction
03. Market Coverage
Market Overview
Key Offerings
04. Market Landscape
Market Size and Forecast
04.1 Five Forces Analysis
05. Geographical Segmentation
06. Rate of Incidence and Prevalence
07. Vendor Landscape
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Key Vendor Analysis
14.1 F. Hoffmann-La Roche Ltd.
Business Overview
Key Information
SWOT Analysis
14.2 AstraZeneca plc
Business Overview
Key Information
SWOT Analysis
14.3 Eli Lilly & Co.
Business Overview
Key Information
SWOT Analysis
14.4 Sanofi S.A.
Business Overview
Key Information
SWOT Analysis
15. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Non-small Cell Lung Cancer Drugs Market 2012-2016 (US$ billion)
Exhibit 2: Global Non-small Cell Lung Cancer Drugs Market by Geographical Segmentation 2012
Exhibit 3: Global Non-small Cell Lung Cancer Drugs Market by Vendor Segmentation 2012
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
